Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
ERCP (endoscopic retrograde cholangiopancreatography) has been largely demonstrated to be effective in multiple bilio-pancreatic indications. However, one of the feared complication of this technique is acute pancreatitis, which happens in 5 to 25% of cases. Some patient groups have been demonstrated to present a higher risk linked to individual factors or to the procedure. Some interventions (endoscopic or pharmacologic) have been evaluated to reduce the incidence of this complication but each has his own inconvenient. Recently, the activation of heme oxygenase (HO) by intraperitoneal administration of hemin has been demonstrated to be effective in prevention and treatment of acute pancreatitis mice models. This protective effect has been associated to intrapancreatic HO-1 positive macrophage recruitment activated by hemin. The investigators thus propose to conduct a prospective randomized double blind controlled trial to demonstrate a protective effect of hemin administration against post-ERCP acute pancreatitis in high risk patients.
Patients for who a pancreatic stent placement is indicated will be excluded from the study.
The aims of this study are: 1) to study in a pathophysiologic point of view the activation of HO-1 by hemin in human and its protective effect in post-ERCP acute pancreatitis incidence. 2) to use the human situation of post-ERCP acute pancreatitis as early pancreatitis model to study the administration of hemin as treatment of acute pancreatitis in general.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Hemin | Active Comparator | A peripheral perfusion of 4mg/kg of hemin (Normosang) diluted in 100mL NaCL (sodium chloride) 0.9% will be administered in 30-60minutes as soon as possible after the end of the ERCP, followed by 100mL of NacL 0.9% to flush the vein |
|
| Placebo | Placebo Comparator | The same amount of NaCl 0.9% (100 ML followed by a flushing perfusion of 100mL) will be perfused to the patient as soon as possible after the end of the ERCP |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Hemin | Drug | A single perfusion of 4mg/kg hemin diluted in 100mL of NaCl 0.9% administered as soon as possible after the end of the ERCP followed by 100mL of NaCL 0.9% to flush the vein |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of post-ERCP acute pancreatitis | Post-ERCP acute pancreatitis is defined by an abdominal pain compatible with pancreatitis and the elevation of seric lipases more than 3 times the upper limit of normal on days 1 post-ERCP. | at day 1 post-ERCP |
| Measure | Description | Time Frame |
|---|---|---|
| severity of post-ERCP acute pancreatitis | If post-ERCP acute pancreatitis happens, all parameters of severity will be recorded (clinical, biological, intra-abdominal collections seen on abdominal scanner/magnetic resonance, organ failure, need for ICU hospitalization, need for further treatment: surgery/endoscopy/radiological drainage?) | during the hospital stay (up to 2 months) |
| Measure | Description | Time Frame |
|---|---|---|
| number of patients with post-ERCP acute pancreatitis and adverse event at interim analysis | After having randomized 50 patients by arm, an interim analysis will be conducted to evaluate the safety (superficial venous thrombophlebitis, headache, unexpected adverse events)and need to complete the study (depending on the results on post-ERCP acute pancreatitis incidence) | after 100 patients |
Inclusion Criteria: one or more factors of >10% post-ERCP acute pancreatitis risk:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Arnaud Lemmers, MD,PhD | Erasme Hospital, Université libre de Bruxelles (ULB), Brussels, Belgium | Principal Investigator |
| Jacques Devière, MD, PhD | Erasme Hospital, Université Libre de Bruxelles (ULB), Brussels, Blegium | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU Brugmann | Brussels | 1020 | Belgium | |||
| Erasme Hospital, Université Libre de Bruxelles (ULB) |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38431445 | Derived | Yared RA, Chen CC, Vandorpe A, Arvanitakis M, Delhaye M, Viesca MFY, Huberty V, Blero D, Toussaint E, Hittelet A, Verset D, Margos W, Le Moine O, Njimi H, Liao WC, Deviere J, Lemmers A. Intravenous Hemin, a potential heme oxygenase-1 activator, does not protect from post-ERCP acute pancreatitis in humans: Results of a randomized multicentric multinational placebo-controlled trial. Pancreatology. 2024 May;24(3):363-369. doi: 10.1016/j.pan.2024.02.009. Epub 2024 Feb 15. |
Not provided
Not provided
| ID | Term |
|---|---|
| D006427 | Hemin |
| D006418 | Heme |
| C048849 | heme arginate |
| D012965 | Sodium Chloride |
| ID | Term |
|---|---|
| D008665 | Metalloporphyrins |
| D011166 | Porphyrins |
| D045725 | Tetrapyrroles |
| D011758 | Pyrroles |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| placebo | Drug | A single perfusion of 100mL of NaCl 0.9% administered as soon as possible after the end of the ERCP followed by 100mL of NaCL 0.9% to flush the vein |
|
|
| length of stay | the length of stay in the hospital will be recorded. if a complication occurs (post-ERCP acute pancreatitis or other, it will be recorded) | during the hospitalization (up to 2 months) |
| safety of hemin administration | Few side effects of hemin are known (headache, superficial thrombophlebitis in the perfused vein); they will be recorded as well as other unexplained clinico-biological events | within 7 days |
| Brussels |
| 1070 |
| Belgium |
| Centre Hospitalier de Jolimont-Lobbes | Haine-St-Paul | 7100 | Belgium |
| Hôpital Ambroise Paré | Mons | 7000 | Belgium |
| ISPPC CHU Vésale | Montigny-le-Tilleul | 6110 | Belgium |
| National Taiwan University Hospital | Taipei | Taiwan |
| D001393 |
| Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D006576 | Heterocyclic Compounds, 4 or More Rings |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D047028 | Macrocyclic Compounds |
| D011083 | Polycyclic Compounds |
| D010860 | Pigments, Biological |
| D001685 | Biological Factors |
| D002712 | Chlorides |
| D006851 | Hydrochloric Acid |
| D017606 | Chlorine Compounds |
| D007287 | Inorganic Chemicals |
| D017670 | Sodium Compounds |